AtriCure (NASDAQ:ATRC) had its price objective increased by Stifel Nicolaus from $23.00 to $32.00 in a report released on Wednesday. They currently have a buy rating on the medical device company’s stock.
Several other equities analysts have also recently commented on ATRC. Needham & Company LLC reiterated a buy rating and set a $23.00 target price on shares of AtriCure in a research note on Tuesday, February 27th. Canaccord Genuity upped their target price on shares of AtriCure from $24.00 to $26.00 and gave the company a buy rating in a research note on Tuesday, February 27th. ValuEngine upgraded shares of AtriCure from a sell rating to a hold rating in a research note on Wednesday, March 7th. BidaskClub upgraded shares of AtriCure from a hold rating to a buy rating in a research note on Saturday, March 17th. Finally, TheStreet upgraded shares of AtriCure from a d+ rating to a c- rating in a research note on Friday, March 16th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $30.80.
Shares of AtriCure opened at $27.05 on Wednesday, Marketbeat Ratings reports. The company has a quick ratio of 2.31, a current ratio of 3.15 and a debt-to-equity ratio of 0.34. AtriCure has a 1-year low of $14.88 and a 1-year high of $30.96. The firm has a market capitalization of $947.83 million, a PE ratio of -32.59 and a beta of 0.24.
AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, April 26th. The medical device company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.04). The firm had revenue of $46.99 million during the quarter, compared to analyst estimates of $45.43 million. AtriCure had a negative return on equity of 16.92% and a negative net margin of 14.88%. AtriCure’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.32) earnings per share. analysts anticipate that AtriCure will post -0.86 EPS for the current year.
In other AtriCure news, Director Elizabeth D. Krell sold 10,000 shares of the business’s stock in a transaction on Tuesday, May 8th. The shares were sold at an average price of $22.82, for a total value of $228,200.00. Following the sale, the director now owns 29,967 shares of the company’s stock, valued at approximately $683,846.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Mark A. Collar sold 2,090 shares of the business’s stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $25.00, for a total transaction of $52,250.00. Following the completion of the sale, the director now directly owns 66,898 shares in the company, valued at approximately $1,672,450. The disclosure for this sale can be found here. 10.00% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in ATRC. Teacher Retirement System of Texas bought a new stake in AtriCure in the 4th quarter valued at $203,000. Highbridge Capital Management LLC bought a new stake in AtriCure in the 1st quarter valued at $208,000. Trexquant Investment LP bought a new stake in AtriCure in the 1st quarter valued at $224,000. HBK Investments L P bought a new stake in AtriCure in the 4th quarter valued at $255,000. Finally, JPMorgan Chase & Co. increased its holdings in AtriCure by 105.1% in the 1st quarter. JPMorgan Chase & Co. now owns 14,208 shares of the medical device company’s stock valued at $292,000 after buying an additional 7,281 shares during the period. 87.52% of the stock is currently owned by hedge funds and other institutional investors.
AtriCure Company Profile
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.